Cargando…
Management of hyperphosphatemia in patients with end-stage renal disease: focus on lanthanum carbonate
Elevated serum phosphate levels as a consequence of chronic kidney disease (CKD) contribute to the increased cardiovascular risk observed in dialysis patients. Protein restriction and dialysis fail to adequately prevent hyperphosphatemia, and in general treatment with oral phosphate binding agents i...
Autores principales: | Persy, Veerle P, Behets, Geert J, De Broe, Marc E, D’Haese, Patrick C |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3108761/ https://www.ncbi.nlm.nih.gov/pubmed/21694915 |
Ejemplares similares
-
Clinical Evaluation of the Safety, Efficacy and Tolerability of Lanthanum Carbonate in the Management of Hyperphosphatemia in Patients with End-Stage Renal Disease
por: Cernaro, Valeria, et al.
Publicado: (2020) -
The management of hyperphosphatemia by lanthanum carbonate in chronic kidney disease patients
por: Shigematsu, Takashi, et al.
Publicado: (2012) -
Effect of low-dose lanthanum carbonate on calcium and phosphorus metabolism in Asian Patients with end-stage renal disease, maintenance hemodialysis and hyperphosphatemia
por: Cui, Xiaofei, et al.
Publicado: (2022) -
Efficacy of crushed lanthanum carbonate for hyperphosphatemia in hemodialysis patients undergoing tube feeding
por: Kitajima, Yukie, et al.
Publicado: (2011) -
Effect of lanthanum carbonate and calcium acetate in the treatment of hyperphosphatemia in patients of chronic kidney disease
por: Scaria, P. Thomas, et al.
Publicado: (2009)